Cozen O’Connor currently handles Celgene’s non-patent intellectual property matters on a global basis, including trademark, copyright, anti-counterfeiting, enforcements and customs litigation and transactional matters. Celgene is a global biopharmaceutical company with a market cap of and annual sales of more than $105 billion. Its mission is to discover and develop treatments for cancer and other severe inflammatory conditions.
As an example, we are currently handling multiple federal cases in New Jersey in connection with the unauthorized sale of medication outside of restricted distribution channels. We are also currently handling multiple domain names disputes before ICANN.